Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer's disease have been dented by the failure of a phase 2b trial of Johnson & Johnson's posdinemab. The AuTonomy ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results